Table 3.

PASC outcomes between pre- and since Delta variant COVID-19 patients with HIV positive diagnosis after propensity score matching.

Outcome	Pre-Delta	Since-Delta	OR (95% CI)	p-Value
Mortality	225 (5.2%)	97 (2.2%)	2.39 (1.88, 3.05)	<0.001
Hypertension	203 (9.9%)	105 (5.2%)	2.01 (1.58, 2.57)	<0.001
Diabetes	161 (5.0%)	66 (2.0%)	2.54 (1.9, 3.4)	<0.001
Thyroid Disorders	50 (1.2%)	22 (0.5%)	2.29 (1.39, 3.79)	0.001
Heart Disease	226 (7.6%)	115 (4.0%)	1.98 (1.57, 2.49)	<0.001
Malignancy	115 (3.1%)	48 (1.3%)	2.46 (1.75, 3.45)	<0.001
Thrombosis	139 (3.8%)	82 (2.3%)	1.71 (1.29, 2.25)	<0.001
Mental Disorders	211 (10.2%)	120 (6.8%)	1.55 (1.23, 1.96)	<0.001
Rheumatoid Arthritis	11 (0.3%)	10 (0.2%)*	1.1 (0.47, 2.58)	0.834
Respiratory Symptoms	1249 (28.9%)	898 (20.8%)	1.55 (1.4, 1.71)	<0.001
Headache	466 (10.8%)	322 (7.5%)	1.5 (1.29, 1.74)	<0.001
Bodyache	236 (5.5%)	153 (3.5%)	1.57 (1.28, 1.94)	<0.001
Cognitive Impairment	59 (1.4%)	30 (0.7%)	1.98 (1.27, 3.08)	0.002
Hair loss	61 (1.4%)	31 (0.7%)	1.98 (1.28, 3.06)	0.002
Disturbances to Smell and Taste	39 (0.9%)	13 (0.3%)	3.02 (1.61, 5.66)	<0.001
Fatigue	491 (11.4%)	316 (7.3%)	1.62 (1.4, 1.88)	<0.001
Chronic cough	540 (12.5%)	447 (10.3%)	1.24 (1.08, 1.41)	0.002
Brain Fog	119 (2.8%)	75 (1.7%)	1.6 (1.2, 2.15)	0.001
Palpitations	166 (3.8%)	95 (2.2%)	1.78 (1.38, 2.3)	<0.001
Chest pain	830 (19.2%)	600 (13.9%)	1.47 (1.31, 1.65)	<0.001
Sexual desire or capacity	16 (0.4%)	10 (0.2%)*	1.6 (0.73, 3.53)	0.239
Dizziness	343 (7.9%)	237 (5.5%)	1.49 (1.25, 1.76)	<0.001
Gastrointestinal symptoms	1404 (32.5%)	1053 (24.4%)	1.49 (1.36, 1.64)	<0.001
Abnormal movements	124 (2.9%)	78 (1.8%)	1.61 (1.21, 2.14)	0.001

*TriNetX automatically round patient counts of 1-9, up to 10.